Use of ERCC1 gene expression to predict the effectiveness of platin-based therapy in colorectal, ovarian and lung cancer

2541 Background: ERCC1 expression is associated with tumor response, progression free survival and overall survival of cancer patients treated with platin-based therapies. We have determined the optimal cut-point values of ERCC1 gene expression for separating patients with best and worst outcomes from platin-based chemotherapy in 3 different types of cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were obtained from 366 patients with NSCLC treated in a multicenter phase III trial. The regimes were docetaxel plus cisplatin or docetaxel plus gemcitabine. An additional 191 FFPE from patients with metastatic colorectal cancer treated with FOLFOX ± PTK/ZK in first- and second-line treatment enrolled in the CONFIRM 1 and CONFIRM 2 studies were analyzed. Further, we examined 145 ovarian cancer patients treated with carboplatin or cisplatin alone or in combination with docetaxel or paclitaxel. FFPE tissues were microdissected and analyzed for ERCC-1 mRNA expression using quantitative...